China wants 5 innovative drugs with US$1 billion returns by 2030. Which might they be?
The increasing global appeal of Chinese firms’ novel therapies has propelled the country’s rise as a biomedical powerhouse, but China has yet to produce a drug to rival all-time best-selling Western blockbusters in sales. Beijing has set ambitious new five-year targets to boost its global presence, including at least five products with annual global sales surpassing US$1 billion by 2030. The goal…
China aims to achieve groundbreaking achievements in drug development by 2030, targeting five innovative therapies with annual sales of over US$1 billion each. Some leading contenders in this endeavor include BeOne's zanubrutinib, which has already surpassed US$3.9 billion in global revenue as a treatment for blood cancers. Legend Biotech's Carvykti, developed in collaboration with Johnson & Johnson, has also met the sales target, amounting to US$1.9 billion in 2025.
Akeso's ivonescimab, which outperformed Merck's Keytruda in lung cancer trials, has the potential to generate US$8.5 billion in sales by 2032, as projected by Evaluate. Tislelizumab, BeOne's second-highest-grossing drug, and Kelun-Biotech's sacituzumab tirumotecan are also considered strong candidates for reaching the US$1 billion sales milestone by the end of the decade.
Written by urgent.news from SCMP Business's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
